From: Artificial liver support systems: what is new over the last decade?
Study | Years | Design | Patients number | Outcomes | Comments | LOE |
---|---|---|---|---|---|---|
Hessel et al. [39] | 2010 | Controlled, randomized MARS + SMT vs. SMT | 149 | 3-year survival improvement* | Acceptable cost-outcome ratio (measured by cost per LYG and costs per QALY) | 2 |
 |  |  |  |  | Inadequate randomization |  |
Novelli et al. [51] | 2010 | Controlled, non-randomized MARS vs. SMT | 20 | MELD improvement** | Delta MELD predict survival | 2 |
Bañares et al. [38] | 2013 | Controlled, randomized, multicentre MARS + SMT vs. SMT | 156 | No improvement in 28-day and 90-day transplant-free survivals | No differences in 28-day transplant-free survival in subgroups: MELD > 20, HRS at admission, severe HE, and progressive hyperbilirubinemia | 1 |
Gerth et al. [40] | 2017 | Controlled, non-randomized MARS + SMT vs. SMT | 101 | Improvement in 7-day** and 14-day*** transplant-free survivals | No differences in 21-day and 28-day transplant-free survivals | 2 |
 |  |  |  |  | Improvement in estimate 28-day transplant-free survival rate in subgroup of patients with two or more organs failure (CLIF-ACLF grade ≥ 2)* |  |